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Abstract
Background: Carotid angioplasty with stenting is a relatively new, increasingly used, less-invasive
treatment for the treatment of symptomatic carotid artery stenosis. It is being evaluated in ongoing
and nearly finished randomized trials. An important factor in the evaluation of stents is the
occurrence of in-stent restenosis. An un-stented carotid artery is likely to have a more elastic
vessel wall than a stented one, even if stenosis is present. Therefore, duplex ultrasound cut-off
criteria for the degrees of an in-stent stenosis, based on blood velocity parameters, are probably
different from the established cut-offs used for un-stented arteries. Routine criteria can not be
applied to stented arteries but new criteria need to be established for this particular purpose.
Methods/Design: Current literature was systematically reviewed. From the selected studies, the
following data were extracted: publication year, population size, whether the study was
prospective, which reference test was used, and if there was an indication for selection bias and for
verification bias in particular. Previous studies often were retrospective, or the reference test (DSA
or CTA) was carried out only when a patient was suspected of having restenosis at DUS, which
may result in verification bias.
Results: In general, the cut-off values are higher than those reported for unstented arteries.
Previous studies often were retrospective, or the reference test (DSA or CTA) was carried out
only when a patient was suspected of having restenosis at DUS, which may result in verification bias.
Discussion: To address the deficiencies of the existing studies, we propose a prospective cohort
study nested within the International Carotid Stenting Study (ICSS), an international multi-centre
trial in which over 1,700 patients have been randomised between stenting and CEA. In this cohort
we will enrol a minimum of 300 patients treated with a stent. All patients undergo regular DUS
examination at the yearly follow-up visit according to the ICSS protocol. To avoid verification bias,
an additional computed tomography angiography (CTA) will be performed as a reference test in all
consecutive patients, regardless of the degree of stenosis on the initial DUS test.
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Background
Carotid endarterectomy (CEA) is an effective and estab-
lished treatment for secondary prevention of stroke in
patients with symptomatic carotid artery stenosis[1].
Carotid angioplasty with stenting (CAS) is a relatively
new, increasingly used, less-invasive treatment, which is
being evaluated in ongoing or nearly finished randomized
trials, such as the Carotid Revascularization Endarterec-
tomy versus Stent Trial (CREST) and the International
Carotid Stenting Study (ICSS) [2,3]. ICSS finished rand-
omization and will publish its safety results in the short
term. Previous trials that compared CEA with CAS were
rather heterogeneous and not large enough to allow relia-
ble conclusions. Furthermore, because there is limited fol-
low-up information to date, the long-term effect of CAS
remains unclear. We therefore need more data from these
nearly finished randomised trials, including long follow-
up, before recommending if and when stenting should
replace endarterectomy in clinical practice [4,5].
An important factor in the evaluation of stents is the
occurrence of in-stent restenosis. Both the Carotid and
Vertebral Artery Transluminal Angioplasty Study (CAVA-
TAS) and the Stent-Protected Angioplasty versus Carotid
Endarterectomy (SPACE) study reported a higher inci-
dence of restenosis in patients treated with CAS than in
patients treated with CEA [6,7]. However, we do not know
if an in-stent restenosis will give rise to symptoms in a
similar way to atherosclerotic carotid stenosis, and the
clinical consequences of restenosis are yet unknown. In
CAVATAS the majority of patients in the endovascular
arm were treated by angioplasty without stenting. The
SPACE-investigators concluded that it could not be
excluded that the degree of in-stent stenosis was slightly
overestimated by conventional ultrasound criteria. Long
term follow-up data of patients treated with a stent are
needed to investigate the clinical consequences of in-stent
restenosis. Prior to these analyses, to reliably diagnose in-
stent restenosis, we first need reliable duplex ultrasound
cut-off criteria.
Traditionally, the degree of stenosis in an untreated
carotid artery was measured with conventional digital
subtraction angiography (DSA). Because of a small but
non-negligible risk of stroke or death, DSA has been
replaced by non-invasive tests, such as duplex ultrasound
(DUS), CT angiography (CTA) or MR angiography (MRA)
[8-10]. In the follow-up of patients with a stent, DUS is
often used to monitor the patency of the stent and the
occurrence of in-stent restenosis. For routine evaluation of
un-stented carotid arteries, DUS is a well validated diag-
nostic test and the cut-off criteria for the different degrees
of stenosis are clear [8,9]. For measurements within stents,
however, these criteria may not suffice.
In a stenosed artery, narrowing of the lumen results in
higher blood flow velocities at that point. Estimating the
degree of stenosis with DUS is based on this principle. The
peak systolic velocity (PSV) is the best predictor for the
severity of the stenosis [11]. However, the degree of reste-
nosis in a stented carotid artery, measured according to
the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET) criteria on CTA or MRA, is often less
severe than expected based on the PSV in the DUS test.
Possibly, blood flow and blood turbulence behave differ-
ently in an artificial stent than in a normal vessel. This
problem has been addressed in literature before; particu-
larly by Lal en coworkers [12]. An un-stented carotid
artery is likely to have a more elastic vessel wall than a
stented one, even if stenosis is present. The cut-off criteria
for the degrees of an in-stent stenosis, based on blood
velocity parameters, are probably different from the estab-
lished cut-offs used for un-stented arteries. We hypothe-
sise that the PSV raises more in a stented than in a un-
stented carotid artery with a similar degree of stenosis (fig-
ure 1). Additional duplex characteristics may also be dif-
ferent in an in-stent restenosis, such as formation of
Illustration of our hypothesis that a un-stented carotid artery  (A) has a more elastic vessel wall than a stented one (B), and  that the PSV raises more in a stented (D) than in an un- stented carotid artery (C) with a similar degree of stenosis Figure 1
Illustration of our hypothesis that a un-stented 
carotid artery (A) has a more elastic vessel wall than 
a stented one (B), and that the PSV raises more in a 
stented (D) than in an un-stented carotid artery (C) 
with a similar degree of stenosis.BMC Neurology 2009, 9:36 http://www.biomedcentral.com/1471-2377/9/36
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intimal hyperplasia instead of atherosclerotic plaque as
cause of the stenosis. These characteristics need to be stud-
ied as well; the present study, however, will be limited to
definition of PSV criteria. Routine criteria can not be
applied to stented arteries but new criteria need to be
established for this particular purpose.
Valid criteria are needed for future research and clinical
decisions in patients treated with a carotid artery stent. In
this article, we therefore first review the current literature
and discuss the most important limitation of earlier diag-
nostic studies on this topic, verification bias. In the discus-
sion, we describe the design of a new diagnostic study
designed to validate the use of DUS in-stent stenosis
measurements during follow-up after CAS and to deter-
mine reliable cut-off criteria for the different degrees of
stenosis.
Methods/Design
The PubMed databases have been searched from 2000
until 2009 for publications with "duplex ultrasound"
combined with "carotid", "stent" or "in-stent", and "rest-
enosis" as keywords, without language restrictions. Cross-
references and review articles were used for search com-
pletion. In case of more than one publication on this topic
by one group, the most recent or largest series was chosen.
A hand-search of relevant journals and conference pro-
ceedings was not performed. Based on titles and abstracts,
studies evaluating duplex ultrasound for assessment of in-
sent restenosis were selected. To be included in this
review, the study needed to provide duplex ultrasound
cut-off criteria, calculated by comparison with stenosis
measurements on a reference test (CTA or DSA). From the
selected studies, the following data were extracted: publi-
cation year, population size, whether the study was pro-
spective, which reference test was used, and if there was an
indication for selection bias and for verification bias in
particular. A formal and systematic review, and meta-anal-
ysis, will be performed after the presented new diagnostic
study is finished; including its results.
Results
We identified 6 unique diagnostic series on in-stent sten-
osis measurements with DUS compared to a reference test
(CTA or DSA) [13-18]. In one study DUS and CTA were
compared for in-stent measurements, but this paper
needed to be excluded because no new criteria were calcu-
lated [18]. Additional file 1: Table S1 summarises the 5
series that propose new criteria. In general, the cut-off val-
ues are higher than those reported for unstented arteries.
For example, the PSV cut-off value for the diagnosis of a
>70% stenosis varies between 300 and 450 cm/sec. The
reported prevalence of in-stent restenosis was low, which
is likely to reflect limited follow-up. Furthermore, the ref-
erence test was only performed in these previous studies if
stenosis was found on DUS, introducing verification bias.
Lal et al recently reported a relatively large population of
255 CAS procedures [14]. They confirm overestimation of
the degree of in-stent restenosis if regular DUS criteria are
applied. Comparisons were made with CTA and DSA.
During follow-up, patients underwent DSA only if they
were suspected as having restenosis on DUS. Criteria cal-
culated from these data may suffer from verification bias.
All patients in their series underwent CTA at the end of
their follow-up. The latter data should not suffer from ver-
ification bias. In another recent series of Aburahma et al,
selection was made with DUS and only patients with
symptomatic ≥ 50% stenosis or asymptomatic ≥ 80% ste-
nosis were included in their diagnostic study [13]. Apply-
ing their DUS criteria to all stented patients is probably
not correct because of the selection criteria applied. Zhou
et al published a large series but concluded that they infre-
quently found cases of severe stenosis after CAS, and that
a multicentre study is warranted to establish reliable in-
stent DUS criteria [15]. Only Kwon et al reported a series
of patients all undergoing both DUS and the reference
test, CTA. This study, however, was too small (n = 27) to
provide new in-stent cut-off criteria [18].
It is clear from the published data that only small and
preselected populations with in-stent restenosis have been
studied to date. A large study with sufficient patients with
restenosis is therefore needed, as authors of the listed
papers also recognised.
Verification bias
Previous studies often were retrospective, or the reference
test (DSA or CTA) was carried out only when a patient was
suspected of having restenosis at DUS, which may result
in verification bias. Verification bias is introduced if the
decision to perform the reference standard procedure
depends on the results of the test under investigation, pre-
cluding a reliable estimate of the diagnostic accuracy of
the latter [19]. The effect of verification bias is explained
in figure 2. In a diagnostic study in carotid artery stenosis,
in order to obtain valid results, during the follow-up all
patients need to undergo both the reference test and the
test under investigation, regardless of the degree of steno-
sis on the initial DUS test. If patients were selected based
on duplex cut-offs before treatment with CAS, this does
not influence the results. On the contrary, the population
selected based on age, gender, symptoms, and degree of
stenosis prior to treatment, is exactly the domain for a
diagnostic study with this purpose.
Protocol for proposed diagnostic study
To address the deficiencies of the existing studies, we plan
to conduct a prospective cohort study nested within the
International Carotid Stenting Study (ICSS), an interna-
tional multi-centre trial in which over 1,700 patients withBMC Neurology 2009, 9:36 http://www.biomedcentral.com/1471-2377/9/36
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recently symptomatic internal carotid stenosis have been
randomised in equal proportions between stenting and
endarterectomy. The ICSS completed recruitment at the
end of 2008. The trial protocol specifies annual clinical
and ultrasound follow up. A sufficiently large population
can be enrolled and because the study is embedded in the
ICSS, long term follow-up is guaranteed, allowing us to
obtain a larger number of restenoses and therefore more
precise estimates for DUS cut-off criteria. Most impor-
tantly, during the follow-up all patients in the sub-study
will undergo both the reference test of CTA and the test
under investigation, regardless of the degree of stenosis on
the initial DUS test.
Reference test
In the protocol, we will use CTA as the reference test for
in-stent stenosis measurements. A diagnostic test that pro-
vides clear images of the lumen of the internal carotid
artery is crucial, because a NASCET-like stenosis measure-
ment is necessary as a reference to estimate the optimal
PSV cut-offs for DUS. DSA would be preferable for opti-
mal images of the lumen of stented (carotid) arteries.
However, in our opinion, this test would not be ethical
anymore as reference test in this diagnostic study because
of the small but not negligible complication rate. CTA and
MRA are non- or minimally invasive tests providing good
lumen images, enabling a 'NASCET'-like stenosis meas-
urement. MRA is not suitable for visualisation of the
lumen in a stent, due to artefacts in the magnetic field
caused by the material of the stent. Therefore, CTA is the
better choice. The use of intravenous iodinated contrast in
CTA allows excellent images of the lumen of the arteries.
To date, CTA offers high spatial resolution and contrast
resolution, and it is a fast technique. Currently, the quality
of imaging of the lumen of the artery with CTA is compa-
rable to DSA. We realise that CTA is better validated for
non-stented than for stented (carotid) arteries. The diag-
nostic accuracy of CTA compared to DSA, to diagnose a
70–99% stenosis, was calculated in several studies [8,10].
Wardlaw et al., in a recent meta-analysis, reported a sensi-
tivity and specificity of 77% (95% CI: 68–84%) and 95%
(95%CI: 91–97%) respectively [8]. Also, CTA may have
certain pitfalls in measuring in-stent stenosis like blurring
artefacts in the stent. However, given the limitations, we
think CTA is the best choice as a reference test in the
assessment of stenosis measurements [20].
Crucial is the fact that we can compare DUS results to a
technique that provides clear images of the lumen, in
order to investigate if the PSV raises more in a stented
artery than in an unstented artery when the remaining
lumen is the same as. Because patients will be recruited
from multiple centres, the CT scanners will not be identi-
cal and we can only handle this limitation by using com-
parable scan protocols and similar post-processing
techniques. Also, different types of stents will be used. If
these stents do not have the same physical properties, the
PSV's are perhaps slightly different as well [21]. We shall
collect data about the used stents, and in our analyses we
shall investigate if there is a relation between type of stent
and blood flow parameters. However, the advantage of a
multi-centre study is that the results will be widely appli-
cable.
Patients
The diagnostic tests will be performed during routine fol-
low-up of the ICSS trial [3]. The inclusion and exclusion
criteria are listed in Table 1. In short, all patients with a
symptomatic atheromatous carotid stenosis, ≥ 50% by
NASCET criteria, suitable for stenting and surgical endar-
terectomy, can be included for treatment. In addition to
the general ICSS criteria, patients are excluded if they have
a contraindication for the contrast agent used for the CTA,
such as renal failure. In the ICSS, patients have scheduled
follow-up visits at 30 days after treatment, 6 months after
randomisation and then annually. We will ask all patients
who received a stent to participate in this diagnostic study
at their follow-up visit 1 year after treatment, or, for
Example of the effect of verification bias in a hypothetical  true distribution of degree restenosis in patients treated with  a carotid artery stent Figure 2
Example of the effect of verification bias in a hypo-
thetical true distribution of degree restenosis in 
patients treated with a carotid artery stent. If a DUS 
cut-off value of for example 50% stenosis is used to select 
patients for a diagnostic study, only the patients in part B and 
C are included and will undergo the reference test. Patients 
in part A are excluded. The number of patients below a cer-
tain threshold, for example 70% is too low (proportion B 
instead of proportion A and B) and therefore leads to incor-
rect estimates of the diagnostic value, the specificity in partic-
ular. Therefore, DUS criteria obtained from a diagnostic 
study with comparison with the reference test in part B and 
C, can not be applied to routine clinical practice for all 
stented patients (part A, B, and C).BMC Neurology 2009, 9:36 http://www.biomedcentral.com/1471-2377/9/36
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patients included more than one year ago, at the first
(yearly) ICSS follow-up visit thereafter. A separate
informed consent for this diagnostic sub-study informing
the patient about the risks of the extra CTA test is
obtained. The sub-study has received approval from the
Multicentre Research Ethics Committee in the UK. The
complete protocol of ICSS and of the present diagnostic
sub study is available at: http://www.ion.ucl.ac.uk/
cavatas_icss/icss.htm.
Sample size
In a sample size calculation in a diagnostic study, in addi-
tion to an estimation of the prevalence of disease, a preci-
sion of the diagnostic accuracy needs to be defined. We
estimate a prevalence of 10 to 20% in-stent restenosis
(≥50%) one year after treatment with a stent. To obtain
estimates of sensitivity of approximately 90% with a con-
fidence interval of maximally 10%, and a prevalence of
restenosis after one year of 20%, we would require a min-
imum of 172 patients [22]. The estimate of 20% re-steno-
sis is at the upper limit of the values reported in literature.
We used this estimate, because our follow-up interval
(after 1 year or more) will be later than of most published
numbers. If we use 10% restenosis in the sample size cal-
culation, with similar estimates for sensitivity, specificity,
and the confidence interval(s), the number exceeds 300
patients (approximately 350). Because the ICSS included
more than 800 patients treated with a stent, and because
the follow-up of the ICSS will continue for several years,
we expect inclusion of a sufficient high number of
patients.
Diagnostic tests
During the DUS examination, different blood flow veloc-
ity parameters will be recorded. The peak systolic velocity
(PSV) in the stent will be used as our outcome variable
because it is considered the most accurate estimator of the
degree of stenosis for DUS [11]. CTA is used as the refer-
ence test for in-stent stenosis measurements. Because dif-
ferent centres participate, we will work with different CT
machines. However, we will match the protocols. Most
importantly, for the assessment of the degree of stenosis,
multiplanar (MPR) or curved planar reconstructions
(CPR) need to be made [20].
Stenosis measurement
Two independent observers, blinded for clinical informa-
tion and for the results of the other diagnostic tests, will
perform a stenosis measurement on the reconstructed
CTA images, following the Standards for Reporting of
Diagnostic Accuracy (STARD) guidelines [23]. The grade
of stenosis will be measured according to the NASCET cri-
teria [1]. Stenosis measurements in NASCET were done
with DSA. The degree of stenosis was defined as the diam-
eter of the remaining lumen at the stenosis as percentage
of the normal lumen distal to the stenosis. The projection,
lateral, posteroanterior, or oblique, which shows the most
severe stenosis, is used for establishing the degree of sten-
osis. Measurements with CTA should preferable be done
in a comparable manner, in order to correctly apply the
trial-data to the clinical decisions about CEA. Thus, for a
valid comparison with DSA, the percentage of stenosis
will be measured on the MPR or CPR post-processed
images of the internal carotid artery, using the three pro-
jections mentioned above only.
Data analysis
Receiver operating characteristics (ROC) curves will be
constructed for the diagnoses of 70%–99% and 50%–
69% stenosis. The associated optimal sensitivities, specif-
icities, and peak-systolic-velocity thresholds will be
derived from the ROC curves. The main result of the anal-
yses will be optimal cut-off points of duplex for in-stent
Table 1: Inclusion criteria International Carotid Stenting Study (ICSS)
Inclusion criteria
- Symptomatic, extracranial, internal or bifurcation, atheromatous carotid artery stenosis that is suitable for both stenting and surgery and is 
deemed by the randomising clinician to require treatment.
- The severity of the stenosis of the randomised artery should be at least 50% (as measured by NASCET method or non-invasive equivalent).
- Symptoms must have occurred in the 12 months before randomisation. It is recommended that the time between symptoms and randomisation 
should be less than 6 months, but patients with symptoms occurring between 6 and 12 months may be included if the randomising physician 
considers treatment indicated.
- The patient must be clinically stable following their most recent symptoms attributable to the stenotic vessel.
- Patients must be willing to have either treatment, be able to provide informed consent, and be willing to participate in follow-up.
- Patients must be able to undergo their allocated treatment as soon as possible after randomisation.
- Any age greater than 40 may be included. There is no upper age limit.
- Patients should only be randomised if the investigator is uncertain which of the two treatments is best for that patient at that time.
Exclusion criteria
- Patients refusing either treatment.
- Patients unable or unwilling to give informed consent.
- Patients unwilling or unable to participate in follow-up for whatever reason.
- Patients who have had a major stroke with no useful recovery of function within the territory of the treatable artery.BMC Neurology 2009, 9:36 http://www.biomedcentral.com/1471-2377/9/36
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restenosis (not the diagnostic accuracy of duplex) within
the context of the present study.
Meta-analysis
When the present study is completed, we will pool our
data with the other diagnostic studies on this particular
topic available in literature [13-18]. In addition to pooled
weighted estimates of the overall diagnostic accuracy, the
data will be modelled using summary ROC analyses. With
this model it will be possible to investigate the effect of
important quality criteria of the individual studies on the
diagnostic accuracy, such as sample size, duration of fol-
low-up, and presence of verification bias.
Discussion
Carotid angioplasty with stenting (CAS) is being evalu-
ated in ongoing randomized trials. An important factor in
the evaluation of carotid artery stents is the degree of pos-
sible in-stent restenosis. DUS is a fast and easy test to asses
the degree of stenosis. Whereas this diagnostic tool is well
validated for stenosis measurements in un-stented carotid
arteries, precise cut-off criteria for stented carotid arteries
are not available yet. The aim of the proposed study is to
validate the use of DUS for in-stent stenosis measure-
ments during follow-up after CAS and to determine relia-
ble cut-off criteria for the different degrees of stenosis.
Valid criteria are needed for future research and clinical
decision making in patients treated with a carotid artery
stent. In conclusion, the ongoing ICSS study provides a
unique opportunity to obtain valid DUS in-stent criteria
in a sufficiently large population, with a long follow-up
and expected high prevalence of restenosis. Verification
bias will be avoided by performing both DUS and CTA in
all patients. Afterwards, our data will be pooled with other
studies, taking into account the limitations of individual
studies.
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